Wu, Jian

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,124

PROTAC-DB: an online database of PROTACs

Weng, G., Shen, C., Cao, D., Gao, J., Dong, X., He, Q., Yang, B., Li, D., Wu, J., & Hou, T. (2021) · Nucleic Acids Research

Protein Degradation and InhibitorsComputational Drug Discovery Methods

Cited by 219

Deep learning of cross-species single-cell landscapes identifies conserved regulatory programs underlying cell types

Li, J., Wang, J., Zhang, P., Wang, R., Mei, Y., Sun, Z., Fei, L., Jiang, M., Ma, L., E, W., et al. (2022) · Nature Genetics

Single-cell and spatial transcriptomicsGenomics and Chromatin Dynamics

Cited by 57

BAG3 and HIF-1 α Coexpression Detected by Immunohistochemistry Correlated with Prognosis in Hepatocellular Carcinoma after Liver Transplantation

Xiao, H., Tong, R., Cheng, S., Lv, Z., Ding, C., Du, C., Xie, H., Zhou, L., Wu, J., & Zheng, S. (2014) · BioMed Research International

Hepatocellular Carcinoma Treatment and PrognosisCancer, Hypoxia, and Metabolism

Cited by 20